 ADMA Biologics Inc NASDAQ: ADMA closed a debt refinancing with Hayfin Capital Management of 150 million, and up to an additional 25 million tied to specific revenue targets during 2022. The first tranche of the newly issued loan from Hayfin was fully drawn and used to completely repay the. 